Unraveling the Genetic Roots of Bicuspid Aortic Valve in Neonatal Heart Development

Bicuspid aortic valve (BAV), the most common congenital heart defect, affects approximately 1-2% of the general population, with a higher incidence in males at a ratio of about 3:1. This condition occurs when the aortic valve, which normally has three leaflets or cusps to regulate blood flow from the heart to the aorta, develops with only two fused leaflets. While many individuals with BAV remain asymptomatic for years, the defect can lead to serious complications such as aortic stenosis, regurgitation, thoracic aortic aneurysms, and even dissection, often requiring surgical intervention later in life.

In Canada, where heart valve disease impacts an estimated 2.5% of the population—rising sharply to 13% after age 75—BAV represents a significant public health concern. Recent advancements in genomic research, particularly from Canadian universities, are shedding light on its genetic underpinnings, offering hope for better prevention and management strategies.

Breakthrough Study from Circulation: A Polygenic Perspective

A landmark study published in February 2026 in the journal Circulation has identified genetic causes of BAV linked to neonatal heart development. Titled "Genome and Transcriptome-Wide Analyses Identify Multiple Candidate Genes and a Significant Polygenic Contribution in Bicuspid Aortic Valve," the research reveals that variations in 36 genetic regions—32 of them novel—increase BAV risk. This international effort, involving over 65,000 participants from the U.S., Canada, and Europe, underscores BAV as a polygenic disorder driven by many common genetic variants rather than rare single mutations.

Co-led by Simon C. Body from Boston University Chobanian & Avedisian School of Medicine and researchers from Laval University in Quebec City, the study highlights the collaborative power of global consortia like the Bicuspid Aortic Valve Consortium. Notably, Yohan Bossé, who holds a Canada Research Chair in Genomics of Heart and Lung Diseases at Laval, played a key role, exemplifying Canada's leadership in cardiovascular genomics.

Decoding the Methodology: GWAS and Beyond

The researchers conducted a genome-wide association study (GWAS) meta-analysis on 9,631 BAV cases. They integrated RNA sequencing from human fetal and adult aortic valve tissues to prioritize genes expressed during critical developmental windows. Colocalization, Mendelian randomization, and functional validation in zebrafish models confirmed causal candidates. For instance, knocking down or knocking out genes like WNT4, LEF1, STRN, and KANK2 disrupted cardiac valve formation in the fish model, mirroring human pathology.

A polygenic risk score (PRS) derived from these loci showed a 2.07 odds ratio per standard deviation for BAV, with links to thoracic aortic aneurysm and atrial fibrillation. This step-by-step approach—from population genotyping to experimental validation—provides a robust framework for future genetic studies.

Spotlight on Key Genes Active in Neonatal Heart Development

During neonatal heart development, the aortic valve forms from endocardial cushions in the outflow tract around weeks 5-9 of gestation. Neural crest cells, second heart field progenitors, and epicardial signals orchestrate leaflet stratification and remodeling. Disruptions here lead to fusion of the right and left coronary cusps, the most common BAV phenotype.

The study prioritized 55 genes, with KANK2 and ERBB4 emerging as top causal candidates via aortic valve transcriptomics. KANK2 regulates cytoskeletal dynamics crucial for cell migration in valve primordia, while ERBB4 signaling pathways govern epithelial-mesenchymal transitions. PRDM6 and STRN were highlighted from aortic and ventricular tissues, respectively. These genes' activity peaks in fetal stages, explaining BAV's congenital nature.

• KANK2: Cytoskeleton regulator, implicated in valve cell migration.
• ERBB4: Receptor tyrosine kinase for heart morphogenesis.
• PRDM6: Transcriptional repressor in aortic tissues.
• STRN: Scaffold protein affecting ventricular signaling.

Understanding these pathways could inspire targeted therapies to prevent fusion during critical developmental windows.

The Power of Polygenic Risk Scores in Predicting BAV Complications

Unlike monogenic diseases, BAV's heritability stems from cumulative effects of common variants. Individuals in the top 10% of PRS face a three-fold higher risk. This score not only predicts BAV but also stratifies complications like aneurysms, where some loci overlap with aortic stenosis genes.

In clinical practice, PRS could guide surveillance intensity, though echocardiography remains the diagnostic gold standard. For Canadian patients, integrating PRS into national registries could optimize resource allocation amid rising valve surgeries.Read the full Circulation study.

Canada's Vanguard: Laval University and Research Chairs Program

Laval University's Institut universitaire de cardiologie et de pneumologie de Québec (IUCPQ) is at the forefront, with Yohan Bossé's team leveraging genomics to dissect BAV. As a Canada Research Chair, Bossé exemplifies how this federal program fuels world-class higher education research. Other Canadian hubs like SickKids Hospital in Toronto, via Seema Mital's lab and the MIBAVA network, explore BAV aortopathy mechanisms.

This study reinforces Canada's role in congenital heart research, supported by CIHR and Heart & Stroke Foundation grants. Aspiring researchers can find opportunities at institutions like Laval through higher ed research jobs.Learn more about IUCPQ research chairs.

Clinical Implications: From Screening to Precision Medicine

First-degree relatives of BAV patients face up to 20-30% risk, prompting guidelines for echocardiographic screening. The study cautions against routine genetic testing due to polygenic complexity but envisions PRS-enhanced risk models. In Canada, where BAV accounts for many young adult valve surgeries, early detection could reduce morbidity.

• Annual echoes for index cases and family.
• Monitor aortic root dilation >4.5 cm.
• Lifestyle: blood pressure control, avoid intense lifting.

Stakeholder views from cardiologists emphasize multidisciplinary care involving geneticists and surgeons.

Stakeholder Perspectives and Real-World Impacts

Patients and families welcome genetic insights for demystifying heritability. Experts like Body stress: "Echocardiography remains key." Canadian clinicians note higher BAV detection via prenatal screening. Economically, BAV complications burden healthcare; predictive tools could save costs.SickKids Mital Lab on BAV.

Cultural context in Canada: diverse populations may influence variant prevalence, urging inclusive GWAS.

Future Outlook: Therapeutic Horizons and Research Needs

CRISPR editing of candidate genes or small molecules targeting ERBB4 pathways hold promise. Longitudinal studies on PRS validation and drug repurposing are next. Canadian universities lead with trials like BAVCon. For higher ed, this spurs genomics programs; check academic CV advice for research roles.

Photo by Ekke Krosing on Unsplash

Career Pathways in Cardiovascular Genetics Research

This study highlights demand for geneticists, bioinformaticians, and clinician-scientists. Canada Research Chairs attract top talent. Explore university jobs or Canada higher ed opportunities. Rate professors shaping the field at Rate My Professor.

In summary, the genetic causes of bicuspid aortic valve identified in neonatal heart development via this Canada Research Chair study pave the way for transformative care. Visit higher ed jobs, rate my professor, and higher ed career advice to join the vanguard.